Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
Joint Authors
Zhang, Yi
Sun, Shangjun
Hao, He
Yang, Ge
Fu, Yang
Source
Journal of Immunology Research
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-04-17
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
T cells modified via chimeric antigen receptors (CARs) have emerged as a promising treatment modality.
Unparalleled clinical efficacy recently demonstrated in refractory B-cell malignancy has brought this new form of adoptive immunotherapy to the center stage.
Nonetheless, its current success has also highlighted its potential treatment-related toxicities.
The adverse events observed in the clinical trials are described in this review, after which, some innovative strategies developed to overcome these unwanted toxicities are outlined, including suicide genes, targeted activation, and other novel strategies.
American Psychological Association (APA)
Sun, Shangjun& Hao, He& Yang, Ge& Zhang, Yi& Fu, Yang. 2018. Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies. Journal of Immunology Research،Vol. 2018, no. 2018, pp.1-10.
https://search.emarefa.net/detail/BIM-1191763
Modern Language Association (MLA)
Sun, Shangjun…[et al.]. Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies. Journal of Immunology Research No. 2018 (2018), pp.1-10.
https://search.emarefa.net/detail/BIM-1191763
American Medical Association (AMA)
Sun, Shangjun& Hao, He& Yang, Ge& Zhang, Yi& Fu, Yang. Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies. Journal of Immunology Research. 2018. Vol. 2018, no. 2018, pp.1-10.
https://search.emarefa.net/detail/BIM-1191763
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1191763